Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report-Reference-Cited by-同舟云学术

Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report

Published:2021-02 Issue:2 Volume:110 Page:594-609
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Mitra Amitava,Suarez-Sharp Sandra,Pepin Xavier J.H.,Flanagan Talia,Zhao Yang,Kotzagiorgis Evangelos,Parrott Neil,Sharan Satish,Tistaert Christophe,Heimbach Tycho,Zolnik Banu,Sjögren Erik,Wu Fang,Anand Om,Kakar Shefali,Li Min,Veerasingham Shereeni,Kijima Shinichi,Lima Santos Gustavo Mendes,Ning Baoming,Raines Kimberly,Rullo Greg,Mandula Haritha,Delvadia Poonam,Dressman Jennifer,Dickinson Paul A.,Babiskin Andrew

Funder

Center of Excellence in Regulatory Science and Innovation

CERSI

University of Maryland

US Food & Drug Administration

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference13 articles.

1. Current state and future expectations of translational modeling strategies to support drug product development, manufacturing changes and controls: a workshop summary report;Pepin;J Pharm Sci,2020

2. Clinical relevance of dissolution testing in quality by design;Dickinson;AAPS J,2008

3. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link—a workshop summary report;Heimbach;AAPS J,2019

4. Dissolution and translational modeling strategies enabling patient-centric drug product development: the M-CERSI workshop summary report;Abend;AAPS J,2018

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Drug Development ( MIDD ) Regarding Regulatory Requirements and Thinking;Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0;2024-06-21

2. İLAÇLARDA SANAL BİYOEŞDEĞERLİK UYGULAMALARI;Ankara Universitesi Eczacilik Fakultesi Dergisi;2024-06-14

3. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space;The AAPS Journal;2024-06-11

4. Tipifarnib physiologically‐based pharmacokinetic modeling to assess drug–drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients;CPT: Pharmacometrics & Systems Pharmacology;2024-05-28

5. Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables;Pharmaceutics;2024-04-19